Temporary Assessment of Language in Kabuki Syndrome (TALK) Study

Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate communication. These processes can be interrupted in neurodevelopmental conditions. Redenlab are partnering with Boston Children’s Hospital on the Temporary Assessment of Language in Kabuki syndrome (TALK) study.

The TALK study is exploring speech and language patterns in individuals with Kabuki syndrome through a collaboration between the Roya Kabuki Program at Boston Children’s Hospital and Redenlab.

Prof Olaf Bodamer (Boston) and Profs Adam Vogel and Angela Morgan (Melbourne) are driving the study design and analysis with the aim of refining clinical trial outcome measures for clinical care and future trials.

Boston Children’s Hospital established a Kabuki Syndrome Program in 2017 to integrate the care, management, and treatment of children and adults with Kabuki syndrome and to conduct research aimed at identifying targeted therapies.

To find out more, and if you are interested in participating in this study, please click here.

Related Post

  • Posted on 27 April, 2023
    Redenlab have been featured in the Huberman Lab Podcast for their study on “Adults with a history of recreational cannabis...
    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      • Posted on 30 March, 2023
        Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision...